SLS
SLS
NASDAQ · Biotechnology

Sellas Life Sciences Group I

Mid-Cap Stocks Biotech Stocks Healthcare Stocks
$10.01
-0.28 (-2.72%)
As of Aug 8, 1:52 AM ET ·
Analyst Consensus
Strong Buy
6
Analysts
Moderate
Coverage
Buy 5 83%
Hold 1 17%
Sell 0 0%
Price Target
Analyst Price Target +238.7% upside
Low Target $25.20
Average Target $33.90
High Target $43.49
Current Price $10.01
Current
$10.01
Target
$33.90
$25.20 $33.90 avg $43.49
Scenario Analysis
Bear Case
$25.20
151.7%
Low target
Base Case
$33.90
+238.7%
Avg target
Bull Case
$43.49
+334.5%
High target
Risk/Reward
2.2x
Favorable
Price in Context
52-Week High
$15.88
-37.0% from high
52-Week Low
$1.39
+620.1% from low
Target vs 52W High
$33.90
+113.5% vs high
Next Earnings Report
Aug 10, 2026
1d
tomorrow
EPS Est: $-0.05
Earnings in 1 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
 Strong Buy 39 79% $257.58 +4.7%
AMGN
Amgen Inc
 Hold 43 49% $190.87 -53.6%
GILD
Gilead Sciences Inc
 Strong Buy 37 81% $362.68 +172.3%
VRTX
Vertex Pharmaceuticals Inc
 Strong Buy 40 83% $438.34 -11.6%
REGN
Regeneron Pharmaceuticals
 Buy 38 71% $76.80 -90.2%
NTRA
Natera Inc
 Strong Buy 30 87% $142.91 -55.6%
RVMD
Revolution Medicines Inc
 Strong Buy 29 93% $114.11 -44.4%
BIIB
Biogen Inc
 Buy 44 64% $91.45 -56.0%